Related Experiment Video
Updated: May 14, 2025

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
HDL-Apolipoprotein in Alzheimer's Disease Revisited: From Periphery to CNS
Yihong Huang1, Jingyi Tang2, Guohua Chen1
1Department of Neurology Houjie Hospital and Clinical College of Guangdong Medical University Dongguan Guangdong China.
Abstract:
High-density lipoprotein (HDL), as a crucial component of lipid metabolism, have roles in regulating Alzheimer's disease (AD) core pathology amyloid β (Aβ) and phosphorylated tau (p-tau) through its apolipoproteins, which are associated with brain structures, cognition, and risk of dementia. The pool of HDL apolipoproteins-in the brain and in the periphery-has its own distinct origin, composition, and regulatory mechanisms. It remains unclear whether these apolipoproteins in the periphery and CNS play distinct roles in the pathogenesis of AD. Specifically, this review focus on the distinct associations of apolipoprotein AI and apolipoprotein E-the major components of HDL in the blood and CSF-with pathological proteins, brain integrity, cognition, and dementia progression in AD. We summarize and examine the current state of knowledge on the values of these apolipoproteins in AD pathogenesis and clinical potential.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment
Role of Neurotransmitters in Memory
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Inflammation

